Diabetes Mellitus Archives - Medical Conferences

Sotagliflozin SCORED MACE benefit

Presented By

Prof. Deepak Bhatt, Brigham and Women's Hospital, USA

Trial

Phase 3, SCORED

Conference

ACC 2022

15 June, 2022 14:57

Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes

Presented By

Dr Ameenathul Fawzy, Liverpool Heart and Chest Hospital, UK

Conference

EHRA 2022

1 June, 2022 11:03

High treatment success with ixekizumab in patients with psoriasis and diabetes

Presented By

Dr Alexander Egeberg, Copenhagen University Hospital Gentofte, Denmark

Trial

Phase 3, UNCOVER

Conference

PFGC 2021

3 February, 2022 11:15

CHIEF-HF: Canagliflozin improves health status in heart failure

Presented By

Prof. John Spertus, University of Missouri-Kansas City, USA

Trial

Phase 3, CHIEF-HF

Conference

AHA 2021

14 January, 2022 14:59

VOYAGER PAD: Fragile or diabetic patients also benefit from rivaroxaban

Presented By

Prof. Cecilia Low Wang, University of Colorado, USA

Trial

VOYAGER PAD

Conference

ESC 2021

26 October, 2021 16:24

Antagonising the mineralocorticoid receptor beneficial for patients with diabetes and CKD

Presented By

Prof. Bertram Pitt, University of Michigan School of Medicine, USA

Trial

Phase 3, FIGARO-DKD

Conference

ESC 2021

26 October, 2021 12:40

2021 ESC Guidelines on Heart Failure

Presented By

Prof. Carolyn Lam, Duke-NUS Medical School, Singapore

Conference

ESC 2021

26 October, 2021 12:34

2021 ESC Guidelines on Cardiovascular Disease Prevention

Presented By

Prof. Frank Visseren, Guidelines Task Force Chair

Conference

ESC 2021

26 October, 2021 11:52

Novel mineralocorticoid receptor antagonist effective irrespective of HF history

Presented By

Prof. Gerasimos Filippatos, Attikon University Hospital, Greece

Trial

FIDELIO-DKD

Conference

HFA 2021

19 August, 2021 16:05

Empagliflozin linked to lower cardiovascular risk and renal events in real-world study

Presented By

Prof. Leo Niskanen, University of Eastern Finland, Finland

Conference

HFA 2021

19 August, 2021 09:43

Efficacy of dapagliflozin and empagliflozin not influenced by diabetes status

Presented By

Prof. Faiez Zannad, University of Lorraine, France

Trial

EMPEROR-Reduced; DAPA=HF; DAPA-CKD; EMPA-Kideney

Conference

HFA 2021

19 August, 2021 09:39

Biomarker panel predicts SGLT2 inhibitor response

Presented By

Dr Muthiah Vaduganathan, Brigham and Women´s Hospital, MA, USA

Trial

CANVAS

Conference

HFA 2021

19 August, 2021 09:33

JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA

Presented By

Dr Anja Strangfeld, German Rheumatism Research Centre Berlin, Germany

Conference

EULAR 2021

2 August, 2021 23:53

Finerenone reduces the risk of AF onset in patients with CKD and diabetes

Presented By

Prof. Gerasimos Filippatos, Attikon University Hospital, Greece

Trial

Phase 3, FIDELIO-DKD

Conference

ACC 2021

9 July, 2021 13:46

DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status

Presented By

Prof. John J. McMurray & Prof. Felipe A. Martinez

Trial

Phase 3, DAPA-HF

Conference

AHA 2019

26 February, 2020 19:16

Phase 3 BETonMACE trial did not meet its primary endpoint

Presented By

Prof. Kausik K. Ray, Imperial College London, United Kingdom

Trial

Phase 3, BETonMACE

Conference

AHA 2019

26 February, 2020 15:47

New guidelines on the prevention of cardiovascular conditions

Presented By

Prof. Roger S. Blumenthal, Johns Hopkins University, USA

Conference

AHA 2019

26 February, 2020 14:36

Penile prosthesis implantation

Presented By

Dr Mahmoud Osman, Dr Mohamad Habous, Prof. Thomas Ahlering , Dr Frederico Dehò

Trial

PHOENIX

Conference

EAU 2019

21 May, 2019 12:50